Dihydromyricetin improves cardiac insufficiency by inhibiting HMGB1 in diabetic rats.
10.12122/j.issn.1673-4254.2022.05.03
- Author:
Si Yu LIU
1
;
Qing LIU
1
;
Qun Long PENG
1
;
Yuan Fang ZHANG
1
;
Jun Jie WANG
1
Author Information
1. Department of Pharmacology, Xiangnan University, Chenzhou 423000, China.
- Publication Type:Journal Article
- Keywords:
cardiac insufficiency;
dihydromyricetin;
high mobility group protein-1;
nuclear factor-κB p65;
type 2 diabetes mellitus
- MeSH:
Animals;
Diabetes Mellitus, Experimental/metabolism*;
Diabetes Mellitus, Type 2/metabolism*;
Flavonols;
HMGB1 Protein;
Heart Failure;
Male;
Metformin/therapeutic use*;
NF-kappa B/metabolism*;
Rats;
Rats, Sprague-Dawley
- From:
Journal of Southern Medical University
2022;42(5):641-648
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the effect of dihydromyricetin (DHM) on cardiac insufficiency in diabetic rats and explore the underlying mechanism.
METHOD:Twenty-four male SD rats were randomized equally into normal control group, type 2 diabetes (T2DM) group fed on a high-glucose and high-fat diet for 6 weeks with low-dose streptozotocin (STZ) injection, metformin (MET) group with daily intragastric administration of MET (150 mg/kg) for 8 weeks after T2DM modeling, and dihydromyricetin (DHM) group with daily intragastric administration of DHM (250 mg/kg) for 8 weeks after modeling. The levels of fasting blood glucose, low density lipoprotein (LDL-C), triglyceride (TG), total cholesterol (TC), high density lipoprotein (HDL-C) and glycosylated hemoglobin (HbA1c) of the rats were measured, and plasma levels of insulin and high mobility group protein-1 (HMGB1) were detected with ELISA. The cardiac function of the rats was assessed using color echocardiography, ECG was measured using a biological signal acquisition system, and myocardial pathology was observed with HE staining. The protein expressions of HMGB1, nuclear factor-κB (NF-κB) p65 and phospho-NF-κB p65 (p-NF-κB p65) in the myocardial tissue were detected using Western blotting.
RESULTS:Compared with the control group, the rats in T2DM group showed significant anomalies in cardiac function after modeling with significantly increased plasma HMGB1 level and expressions of HMGB1, NF-κB p65 and p-NF-κB p65 proteins in the myocardial tissue (P < 0.05 or 0.01). Treatment with DHM significantly improved the indexes of cardiac function of the diabetic rats (P < 0.05 or 0.01), decreased plasma HMGB1 level and down-regulated the protein expressions of HMGB1 and p-NF-κB p65 in the myocardial tissue (P < 0.05 or 0.01).
CONCLUSION:DHM treatment can improve cardiac function in diabetic rats possibly by down-regulation of HMGB1 and phospho-NF-κB p65 expressions in the myocardium.
